Ventas Valuation
Is 0LO4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0LO4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0LO4 ($64.85) is trading below our estimate of fair value ($88.33)
Significantly Below Fair Value: 0LO4 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0LO4?
Key metric: As 0LO4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0LO4's PS Ratio? | |
|---|---|
| PS Ratio | 5.6x |
| Sales | US$4.80b |
| Market Cap | US$27.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.4x |
| Enterprise Value/EBITDA | 21.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0LO4's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.2x | ||
PHP Primary Health Properties | 7.2x | -0.4% | UK£1.3b |
AGR Assura | 7.8x | 4.8% | UK£1.3b |
THRL Target Healthcare REIT | 7.6x | 3.2% | UK£527.8m |
CRT Care REIT | 6.5x | 6.0% | UK£346.0m |
0LO4 Ventas | 5.6x | 7.4% | US$27.1b |
Price-To-Sales vs Peers: 0LO4 is good value based on its Price-To-Sales Ratio (5.6x) compared to the peer average (7.2x).
Price to Sales Ratio vs Industry
How does 0LO4's PS Ratio compare vs other companies in the Global Health Care REITs Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 0LO4 is good value based on its Price-To-Sales Ratio (5.6x) compared to the Global Health Care REITs industry average (6.7x).
Price to Sales Ratio vs Fair Ratio
What is 0LO4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.6x |
| Fair PS Ratio | 10.3x |
Price-To-Sales vs Fair Ratio: 0LO4 is good value based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (10.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$64.85 | US$70.37 +8.5% | 7.0% | US$79.00 | US$55.00 | n/a | 19 |
| Nov ’25 | US$64.30 | US$67.74 +5.3% | 7.6% | US$76.00 | US$55.00 | n/a | 19 |
| Oct ’25 | US$63.86 | US$65.26 +2.2% | 8.8% | US$73.00 | US$55.00 | n/a | 19 |
| Sep ’25 | US$61.70 | US$61.68 -0.03% | 7.9% | US$70.00 | US$50.00 | n/a | 19 |
| Aug ’25 | US$54.94 | US$56.55 +2.9% | 8.9% | US$69.00 | US$49.00 | n/a | 19 |
| Jul ’25 | US$50.87 | US$54.56 +7.3% | 8.8% | US$69.00 | US$49.00 | n/a | 18 |
| Jun ’25 | US$50.14 | US$53.51 +6.7% | 9.1% | US$69.00 | US$49.00 | n/a | 18 |
| May ’25 | US$44.37 | US$52.42 +18.1% | 11.0% | US$70.00 | US$46.00 | n/a | 19 |
| Apr ’25 | US$43.55 | US$52.84 +21.3% | 11.0% | US$70.00 | US$46.00 | n/a | 19 |
| Mar ’25 | US$43.80 | US$53.05 +21.1% | 11.1% | US$72.00 | US$46.00 | n/a | 20 |
| Feb ’25 | US$46.68 | US$54.30 +16.3% | 10.4% | US$72.00 | US$47.00 | n/a | 20 |
| Jan ’25 | US$50.17 | US$52.63 +4.9% | 11.2% | US$72.00 | US$47.00 | n/a | 19 |
| Dec ’24 | US$46.99 | US$51.95 +10.6% | 10.8% | US$72.00 | US$47.00 | n/a | 19 |
| Nov ’24 | US$42.18 | US$52.16 +23.7% | 16.7% | US$80.00 | US$44.00 | US$64.30 | 19 |
| Oct ’24 | US$42.06 | US$53.61 +27.5% | 15.7% | US$80.00 | US$47.00 | US$63.86 | 18 |
| Sep ’24 | US$43.74 | US$52.28 +19.5% | 9.5% | US$68.00 | US$45.00 | US$61.70 | 18 |
| Aug ’24 | US$48.64 | US$53.39 +9.8% | 9.3% | US$68.00 | US$45.00 | US$54.94 | 18 |
| Jul ’24 | US$46.96 | US$54.44 +15.9% | 14.4% | US$80.00 | US$45.00 | US$50.87 | 18 |
| Jun ’24 | US$43.93 | US$53.95 +22.8% | 13.9% | US$80.00 | US$45.00 | US$50.14 | 20 |
| May ’24 | US$46.90 | US$53.71 +14.5% | 14.1% | US$80.00 | US$45.00 | US$44.37 | 21 |
| Apr ’24 | US$42.61 | US$55.20 +29.6% | 13.6% | US$80.00 | US$45.00 | US$43.55 | 20 |
| Mar ’24 | US$46.90 | US$55.05 +17.4% | 13.8% | US$80.00 | US$45.00 | US$43.80 | 21 |
| Feb ’24 | US$51.17 | US$54.20 +5.9% | 14.3% | US$80.00 | US$45.00 | US$46.68 | 22 |
| Jan ’24 | US$44.87 | US$52.89 +17.9% | 15.8% | US$80.00 | US$45.00 | US$50.17 | 22 |
| Dec ’23 | US$46.57 | US$53.20 +14.3% | 16.2% | US$80.00 | US$45.00 | US$46.99 | 22 |
| Nov ’23 | US$38.55 | US$54.70 +41.9% | 18.2% | US$80.00 | US$38.00 | US$42.18 | 22 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Xior Student Housing
€1.3b
Xior Student Housing NV is the first Belgian public regulated real estate company (RREC) specialising in the student housing segment in Belgium, the Netherlands, Spain, Portugal, Germany, Poland, Denmark and Sweden.
0RD8
€30.40
7D
1.7%
1Y
-3.0%
Care Property Invest
€455.7m
Care Property Invest NV/SA is a Public Regulated Real Estate Company (public RREC) under Belgian law.
0R6H
€12.32
7D
2.0%
1Y
-3.9%
Montea Comm. VA
€1.5b
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specializes in logistics real estate in Belgium, the Netherlands, France, and Germany.
0LBY
€66.50
7D
4.3%
1Y
-13.8%